Pfizer hands LianBio $70M to tag along Perceptive's China play, with an eye to beefing up regional portfolio

When Perceptive unveiled its carefully curated syndicate for LianBio’s $310 million Series A, Pfizer stood out as the only pharma amid a marquee group of VCs. It turns out that the drugmaker wasn’t only looking to share the fruits of Lian’s labor, it also wants to get down into the trenches.